KRAS and neoplasm: Consistent with a recent, large study of tissue NGS results for mPDAC14, there was no significant difference in OS or PFS for either PRINCE or SOC patients (or the combined PRINCE and SOC cohort) with a KRAS G12D- versus G12V-bearing tumor (Supplementary Fig. 4).